title: Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives.
abstract: Gastric cancer (GC) is the second leading cause of cancer-related death, and despite having improved treatment modalities over the last decade, for most patients, only modest improvements have been seen in overall survival. Recent progress in understanding the molecular biology of GC and the related signaling pathways offers, from the clinical point of view, promising advances for selected groups of patients. In the past, targeted therapies have significantly impacted the treatment strategy of several common solid tumors such as breast, colorectal, and lung cancers. Unfortunately, translational and clinical research shows fewer encouraging targeted treatments with regards to the GC. To date, only two monoclonal antibodies (mAb), named trastuzumab and ramucirumab, are approved for the treatment of advanced GC, suggesting that in GC, maybe more than in other cancers, effective targeted therapy requires patient selection based on precise predictive molecular biomarkers. The aim of this review is to summarize the available data on the clinical advantages offered by the use of mAbs in the treatment of advanced/metastatic GC. Future perspective is also discussed.
authors.affiliation: Section of pharmacology and University Center DIFF-Drug Innovation Forward Future, Department of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, 25124, Brescia, Italy. giandomenicoroviello@hotmail.it.
authors.forename: Giandomenico
authors.initials: G
authors.lastname: Roviello
authors.affiliation: Department of Medical, Surgical and Neuroscience; Unit of General and Minimally Invasive Surgery, University of Siena, Viale Bracci 11, 53100, Siena, Italy.
authors.forename: Karol
authors.initials: K
authors.lastname: Polom
authors.affiliation: Medical Oncology Unit, University of Siena, Viale Bracci 11, 53100, Siena, Italy.
authors.forename: Roberto
authors.initials: R
authors.lastname: Petrioli
authors.affiliation: General, Minimally Invasive and Robotic Surgery, Department of Surgery, "San Matteo degli Infermi" Hospital, ASL Umbria 2, 06049, Spoleto, Italy.
authors.forename: Luigi
authors.initials: L
authors.lastname: Marano
authors.affiliation: Department of Medical, Surgical and Neurosciences, Section of Advanced Surgical Oncology, University of Siena, Viale Bracci 11, 53100, Siena, Italy.
authors.forename: Daniele
authors.initials: D
authors.lastname: Marrelli
authors.affiliation: Unit of General Medicine, Azienda Ospedaliera "C. Poma " Presidio ospedaliero di Pieve di Coriano, Mantova, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Paganini
authors.affiliation: Department of Surgery and Bioengineering, Section of Surgery, University of Siena, Viale Bracci 11, 53100, Siena, Italy.
authors.forename: Vinno
authors.initials: V
authors.lastname: Savelli
authors.affiliation: Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129, Trieste, Italy.
authors.forename: Daniele
authors.initials: D
authors.lastname: Generali
authors.affiliation: Department of Medical, Surgical and Neurosciences, Section of Advanced Surgical Oncology, University of Siena, Viale Bracci 11, 53100, Siena, Italy.
authors.forename: Lorenzo
authors.initials: L
authors.lastname: De Franco
authors.affiliation: Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Ravelli
authors.affiliation: Department of Medical, Surgical and Neuroscience; Unit of General and Minimally Invasive Surgery, University of Siena, Viale Bracci 11, 53100, Siena, Italy.
authors.forename: Franco
authors.initials: F
authors.lastname: Roviello
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068258:Bevacizumab / Q000627:therapeutic use; D000068818:Cetuximab / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004358:Drug Therapy / Q000379:methods; D066246:ErbB Receptors / Q000737:chemistry; D006801:Humans; D007167:Immunotherapy / Q000379:methods / Q000639:trends; D008453:Maytansine / Q000031:analogs & derivatives / Q000627:therapeutic use; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends; D010166:Palliative Care / Q000379:methods; D000077544:Panitumumab; D015398:Signal Transduction; D013274:Stomach Neoplasms / Q000276:immunology* / Q000628:therapy*; D000068878:Trastuzumab / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000737:chemistry; D000096662:Ramucirumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D000068818:Cetuximab; D066246:ErbB Receptors; D008453:Maytansine; D000077544:Panitumumab; D000068878:Trastuzumab; D042461:Vascular Endothelial Growth Factor A; D000096662:Ramucirumab; C485206:pertuzumab
keywords: Bevacizumab; Gastric cancer; Ramucirumab; Target therapy; Trastuzumab